Institut Godinot — Clinical Trial Site

108 Registered trials

66 Currently recruiting

Organisation

Institut Godinot

Location

Reims, France

Identifier

ORG-100045736

Address

1 Rue Du General Koenig, 51100, France

Departments

/
033016:
Centre d'oncologie
Clinical Research Unit
Département d’oncologie médicale
Department of Hematology and Medical Oncology
Digestive Oncology
gastroenterology
Hepato-gastroenterology
Hepatogastroenterology
Marne
médecine nucléaire
Medical Oncology
Medical oncology department
N/A
NA
Onco-Urology Department #1503
Oncologie
oncologie Digestive
Oncologie médicale
Oncologue
Oncology
oncology department
Oncology-Radiotherapy
Radiotherapist
Radiotherapy
Service d'hématologie et oncologie Médicale
Service d'Oncologie
Service d'oncologie médicale

Clinical trials at this site (108)

Search interface

Randomized trial of avelumab-cetuximab-Radiotherapy versus standards of care in the head and neck cancers Ended

2024-513964-24-00 Squamous cell carcinoma, previously untreated Stage III 5 2017-09-14
Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients (PANIRINOX) Ended

2024-510645-34-00 RAS and B-RAF wild-type metastatic colorectal cancer. R 4 2017-06-28
IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting Ended

2024-517489-41-00 High-risk stage III colon cancer 5 2017-03-27
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patient… Ended

2024-518741-21-00 colon cancer 4 2014-12-23
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free … Ended

2024-516198-61-00 Patients with high risk of relapse, ER+ and HER2- prima 5 2013-06-05
Chemotherapy or chemotherapy + hormonotherapy in women over 70 with HER2 receptor-negative but estrogen receptor-positive breast cancer acco… Ended

2024-516996-34-00 oestrogen-receptor (ER)-positive HER2-negative breast c 5 2012-04-12
Treatment protocol for osteosarcomas in children, adolescents and adults including a randomized trial and biological studies Ended

2024-514756-32-00 High grade osteosarcoma 5 2007-03-19
Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) me… Ended

2022-502372-22-01 Metastatic Breast Cancer HR+, HER2- 4 2023-10-19
Efficacy of immunotherapy in combination with a drug in patients with advanced mucosal cancer of different locations that has progress. Ended

2023-510320-71-00 Squamous cell carcinoma of vulva/vagina 4 2020-10-27
ATTENUATION – A multicenter randomized phase II study of the efficacy and safety de-escalation versus standard adjuvant chemotherapy in pati… Ended

2023-509227-41-00 Low risk of disease recurrence, defined by the followin 4
Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanc… Ended

2024-515533-15-00 Locally advanced cervical cancer 4
PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1)… Ended

2024-519258-35-00 stomach cancer 4